Clinical trials: Alzheimer Dementia (AD), open to volunteers
Alzheimer Disease, Late Onset, Mild Cognitive Impairment
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers
To establish the diagnostic and prognostic models that could help the preclinical identification of subjects at higher risk of clinical progression to mild cognitive impairment and dementia based on combined features of baseline…
- Conditions
- Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Subjective Cognitive Decline
- Trial name
- NCT06561906
- Testing
- Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Alzheimer's Disease (AD)
Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease
With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).
- Trial name
- MOIPAD (NCT06924359)
- Testing
- Multimodal Ophthalmic Imaging and plasma biomarker
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University First Hospital
Mild Cognitive Impairment (MCI), Alzheimer's Dementia (AD)
Expanding Access to Cognitive Health Biomarker Testing at Home
The goal of this observational study is to learn whether at-home blood biomarker testing for Alzheimer's disease risk is feasible and acceptable in older adults with cognitive concerns.
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer's Dementia (AD), Subjective Cognitive Decline (SCD), Cognitive Aging
- Trial name
- NCT07594665
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Virginia
Alzheimer Dementia (AD)
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited.
- Trial name
- NCT07651319
- Testing
- IL-2 (Aldesleukin), Semaglutide Plus IL-2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Methodist Hospital Research Institute
Alzheimer Disease
A Study of AMDX-2011P in Participants With Alzheimer's Disease
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).
- Trial name
- NCT06514001
- Testing
- AMDX-2011P
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Amydis Inc.
Alzheimer Dementia (AD), Diabete Type 2
Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study
Alzheimer's disease is the most common cause of dementia and affects a growing number of older adults. Although harmful proteins build up in the brain, we still do not fully understand why some brain regions are affected earlier…
- Trial name
- PETTAU (NCT07482072)
- Testing
- [18F]FDG PET, [11C]PIB
- Where
- Denmark
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Alzheimer Disease
Novel Personalized Non Invasive Combined Magnetic and Electrical Stimulation of the DMN in Mild AD Patients
Alzheimer's disease (AD) is increasingly recognized as a disorder marked by early synaptic dysfunction and disrupted brain network connectivity, beyond the traditional focus on amyloid pathology.
- Trial name
- CMES_AD (NCT07075770)
- Testing
- Combined iTBS-tACS
- Where
- 2 sites in Italy
- Volunteers
- 60 people
- Sponsor
- I.R.C.C.S. Fondazione Santa Lucia
Prognosis Biomarker of AD, Mild Cognitive Impairment
Marker of Brain Insulin Resistance in AD Prognosis
Basic research data from the literature on the links between cerebral insulin resistance and Alzheimer's disease (AD) suggest that this pathophysiological mechanism is involved at a very early stage in the development of the…
- Conditions
- Prognosis Biomarker of AD, Mild Cognitive Impairment, Brain Insuline Resistance
- Trial name
- IREN (NCT06825663)
- Testing
- Blood punction
- Volunteers
- 122 people
- Sponsor
- Central Hospital, Nancy, France
Frontotemporal Degeneration(FTD), Primary Progressive Aphasia(PPA)
UPenn Observational Research Repository on Neurodegenerative Disease
The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for neurodegenerative disease research and treatment.
- Conditions
- Frontotemporal Degeneration(FTD), Primary Progressive Aphasia(PPA), Familial Frontotemporal Lobar Degeneration (fFTLD), Amyotrophic Lateral Sclerosis(ALS)
- Trial name
- UNICORN (NCT04715399)
- Testing
- No intervention
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Alzheimer's Disease (AD), Mild Cognitive Impairment Due to Alzheimer's Disease
An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease
A multicentre, interventional, multi-arm, multi-stage Phase 3 trial including randomisation, double blinding, placebo control evaluation of treatments for sustained clinical response (18 months) in symptomatic Alzheimer's Disease…
- Conditions
- Alzheimer's Disease (AD), Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer Disease Dementia
- Trial name
- AD-SMART (NCT07724132)
- Testing
- Atomoxetine, Metformin 1000 mg Oral Tablet
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,200 people
- Sponsor
- University College, London
Mild Cognitive Impairment, Alzheimer Disease
Music Therapy for Patients With Alzheimer's Disease
This study is designed to assess the feasibility that individualized reminiscence-based virtual music therapy sessions can enhance autobiographical memory, mood, and cognition in patients with mild cognitive impairment (MCI) or…
- Trial name
- NCT05151562
- Testing
- Virtual Music Therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Johns Hopkins University
Alzheimer s Disease
TSPO Modulation in AD
The aim of this study is to determine whether pharmacological modulation of TSPO (with XBD173, 90mg twice daily, orally, for 28 days) improves neurovascular coupling (NVC) in AD relative to placebo.
- Trial name
- NCT07191821
- Testing
- XBD173
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Alzheimer Disease
Exploratory Study of Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Patients With Mild Alzheimer's Disease Dementia
This randomized, sham-controlled, exploratory clinical trial will evaluate the efficacy and safety of HeLaXON, an investigational low-dose radiation therapy device, in patients with mild Alzheimer's disease dementia.
- Trial name
- LDRT-AD-03 (NCT07863011)
- Testing
- HeLaXON 1X Low-Dose Radiation Therapy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- ReadyCure Inc.
Mild Cognitive Impairment, Alzheimer Disease, Late Onset
Multimodal Assesment of Alzheimer Patients
The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD). The main questions the study aims to answer are: 1.
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Late Onset, Cognitive Impairment, Dementia
- Trial name
- MultiAD (NCT06448403)
- Testing
- MRI Scanning, 64-channel EEG, Polysomnography
- Where
- Norway
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Alzheimer Disease (AD)
Improved Treatment and Monitoring of Alzheimer's Disease
In the world's high-income countries, Alzheimer's disease and other dementia diseases are currently the second most common cause of death.
- Trial name
- NCT07135245
- Testing
- Semaglutide (Rybelsus®) combined with other interventions, Semaglutide (Rybelsus®)
- Volunteers
- 180 people
- Sponsor
- Rune Skovgaard Rasmussen
Alzheimer's Disease (AD), Lewy Body Dementia (LBD)
Social-cognitive Functioning: Validation of a New Neuropsychological Test
It is now established that disturbances in social cognition are frequent in neurology and that they contribute to the development of social conduct disorders.
- Conditions
- Alzheimer's Disease (AD), Lewy Body Dementia (LBD), Frontotemporal Degeneration (FTD)
- Trial name
- REALSOCOG (NCT05558709)
- Testing
- REALSOCOG, BCS, Hetero-questionnaires
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris